-+ 0.00%
-+ 0.00%
-+ 0.00%

Lake Street Maintains Buy on Castle Biosciences, Lowers Price Target to $35

Benzinga·05/06/2025 23:14:04
Listen to the news
Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $40 to $35.